课题基金 / 基金详情

TSP1-CD47 in Promotion of PAH-Associated Vasoconstriction and Vascular Overgrowth

TSP1-CD47 in Promotion of PAH-Associated Vasoconstriction and Vascular Overgrowth
TSP1-CD47 促进 PAH 相关血管收缩和血管过度生长
批准号:
8669813
负责人:
Jeffrey S Isenberg
金额:
$35.75万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2016-05-31

项目摘要

项目成果

Jeffrey S Isenberg的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):肺动脉高压(PAH)是一种以肺血管阻力进行性增加为特征的小肺动脉疾病,导致右心衰竭并最终死亡。血管收缩和血管扩张之间的失衡,再加上血管重构和过度生长是PAH的特征。已知一氧化氮(NO)在PAH中起保护作用,内皮功能衰竭和NO信号的丢失导致人和实验性PAH。主要研究人员最近的工作发现,基质蛋白血栓反应蛋白-1(TSP1)阻断了血管细胞的生理性NO反应。初步数据表明,TSP1与其必需的受体CD47结合,抑制内皮型一氧化氮合酶(ENOS)的激活,从而抑制内皮细胞NO的产生,TSP1和CD47在人和实验性PAH中显著上调。更多的新数据表明,TSP1-CD47网络以PDGF依赖的方式刺激PAH中的血管平滑肌细胞过度生长。在这项建议中要检验的中心假设是,TSP1的过度表达是PAH血管病变的基础,并且与其同源受体CD47的相互作用选择性地调节与微血管反应性、生长和重塑相关的关键第二信使通路。本提案将探讨(I)在PAH中TSP1-CD47上调背后的机制,(Ii)这对血管张力和过度生长的影响,以及(Iii)神经节治疗中断在预防PAH和改善既定疾病方面的效果。
英文摘要
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a disease of the small pulmonary arteries marked by a progressive increase in pulmonary vascular resistance, leading to right heart failure and ultimately death. An imbalance between vasoconstriction and vasodilation coupled with vascular remodeling and overgrowth are hallmarks of PAH. Nitric oxide (NO) is known to play a protective role in PAH and endothelial failure and loss of NO signaling contribute to both human and experimental PAH. Recent work by the principal investigator has found that the matrix protein thrombospondin-1 (TSP1) blocks physiologic NO responses in vascular cells. Preliminary data suggests that TSP1, in binding to its necessary receptor CD47, inhibits activation of endothelial nitric oxide synthase (eNOS) and thus endothelial NO production, and that TSP1 and CD47 are dramatically upregulated in human and experimental PAH. Additional new data demonstrates that the TSP1-CD47 nexus stimulates vascular smooth muscle cell overgrowth in a PDGF-dependent manner in PAH. The central hypothesis to be tested in this proposal is that excessive TSP1 expression underlies PAH vasculopathy and that interaction with its cognate receptor, CD47, selectively regulates key second messenger pathways linked to microvascular vasoreactivity, growth, and remodeling. The present proposal will explore (i) the mechanisms behind upregulation of TSP1-CD47 in PAH, (ii) the implications this has on vascular tone and overgrowth and (iii) the effects that therapeutic interruption of the nexus has on preventing PAH and on ameliorating established disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
TSP-1 and ROS: CD47 and SIRP-alpha as Mediators of Vascular Dysfunction
TSP-1 and ROS: CD47 and SIRP-alpha as Mediators of Vascular Dysfunction
TSP1-CD47 in Promotion of PAH-Associated Vasoconstriction and Vascular Overgrowth
TSP1-CD47 in Promotion of PAH-Associated Vasoconstriction and Vascular Overgrowth
海外基金